The European Medicines Agency recently launched a public consultation on draft Questions and answers on implementation of risk based prevention of cross contamination in production and ‘Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities’ (EMA/CHMP/CVMP/SWP/169430/2012). EIPG has reviewed the document and, following feedback from its members, has submitted its comments to the EMA.
-
-
News from EIPG
- The EU Parliament voted its position on the Unitary SPC
- Reform of pharma legislation: the debate on regulatory data protection
- Environmental sustainability: the EIPG perspective
- How AI is Changing the Pharma Industry and the Industrial Pharmacist’s Role
- Generative AI in drug development
- PGEU annual medicine shortages report
- EMA’s pilot scheme for academic and non-profit development of ATMPs
